Education and Training
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
This randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. The study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: laboratory biomarker analysis
- drug: placebo for study drug
- drug: (RS)2-(3-benzoylphenyl)-propionic acid
Eligibility
Inclusion Criteria:
- Axillary lymph node dissection within the preceding 12 months
Exclusion Criteria:
- Patients with active cancer
- Patients with lymphedema
- Infection or bleeding tendency
- Patients with medical contraindications to nonsteroidal anti-inflammatory drugs
(NSAIDs), including history of allergies, know gastrointestinal intolerance
- Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive
heart failure, neurological or psychological impairment) that would impair the
patients' ability to participate
- Persons not competent to consent
- Patients on aspirin therapy
- Minors (< 18 years of age)
- Pregnant and/or lactating women
- Males
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting